title: Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.
abstract: Myelodysplastic syndromes (MDSs) represent a group of incurable stem-cell malignancies which are predominantly treated by supportive care. Epigenetic silencing through promoter methylation of a number of genes is present in poor-risk subtypes of MDS and often predicts transformation to acute myelogenous leukemia (AML). Azacitidine and decitabine, two FDA-approved DNA methyltransferase (DNMT) inhibitors, are able to improve overall response although their oral bioavailability complicates their clinical use. This study evaluated 2', 3', 5'-triacetyl-5-azacitidine (TAC) as a potential prodrug for azacitidine. The prodrug demonstrated significant pharmacokinetic improvements in bioavailability, solubility, and stability over the parent compound. In vivo analyses indicated a lack of general toxicity coupled with significantly improved survival. Pharmacodynamic analyses confirmed its ability to suppress global methylation in vivo. These data indicate that esterified nucleoside derivatives may be effective prodrugs for azacitidine and encourages further investigation of TAC into its metabolism, activity, and possible clinical evaluation.
authors.affiliation: Nevada Cancer Institute, One Breakthough Way, Las Vegas, NV 89135, USA.
authors.forename: Amy
authors.initials: A
authors.lastname: Ziemba
authors.forename: Eugene
authors.initials: E
authors.lastname: Hayes
authors.forename: Burgess B
authors.initials: BB
authors.lastname: Freeman
authors.forename: Tao
authors.initials: T
authors.lastname: Ye
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pizzorno